+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gallbladder Cancer - Pipeline Review, H2 2019

  • ID: 4901271
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 527 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4SC AG
  • Aslan Pharmaceuticals Ltd
  • Delta-Fly Pharma Inc
  • Hutchison MediPharma Ltd
  • Lokon Pharma AB
  • NuCana Plc
  • MORE
Gallbladder Cancer - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2019, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 19, 14 and 6 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4SC AG
  • Aslan Pharmaceuticals Ltd
  • Delta-Fly Pharma Inc
  • Hutchison MediPharma Ltd
  • Lokon Pharma AB
  • NuCana Plc
  • MORE
Introduction
Gallbladder Cancer - Overview
Gallbladder Cancer - Therapeutics Development
Gallbladder Cancer - Therapeutics Assessment
Gallbladder Cancer - Companies Involved in Therapeutics Development
Gallbladder Cancer - Drug Profiles
Gallbladder Cancer - Dormant Projects
Gallbladder Cancer - Discontinued Products
Gallbladder Cancer - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Gallbladder Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Gallbladder Cancer - Pipeline by 4SC AG, H2 2019
Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H2 2019
Gallbladder Cancer - Pipeline by Almac Discovery Ltd, H2 2019
Gallbladder Cancer - Pipeline by Alphamab Oncology, H2 2019
Gallbladder Cancer - Pipeline by Andes Biotechnologies, H2 2019
Gallbladder Cancer - Pipeline by Apexian Pharmaceuticals Inc, H2 2019
Gallbladder Cancer - Pipeline by Apollomics Inc, H2 2019
Gallbladder Cancer - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
Gallbladder Cancer - Pipeline by AstraZeneca Plc, H2 2019
Gallbladder Cancer - Pipeline by Bayer AG, H2 2019
Gallbladder Cancer - Pipeline by BeiGene Ltd, H2 2019
Gallbladder Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2019
Gallbladder Cancer - Pipeline by Delta-Fly Pharma Inc, H2 2019
Gallbladder Cancer - Pipeline by Diverse Biotech Inc, H2 2019
Gallbladder Cancer - Pipeline by Eisai Co Ltd, H2 2019
Gallbladder Cancer - Pipeline by Eli Lilly and Co, H2 2019
Gallbladder Cancer - Pipeline by Faron Pharmaceuticals Oy, H2 2019
Gallbladder Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2019
Gallbladder Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2019
Gallbladder Cancer - Pipeline by Ipsen SA, H2 2019
Gallbladder Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Gallbladder Cancer - Pipeline by Karus Therapeutics Ltd, H2 2019
Gallbladder Cancer - Pipeline by Kringle Pharma Inc, H2 2019
Gallbladder Cancer - Pipeline by Leap Therapeutics Inc, H2 2019
Gallbladder Cancer - Pipeline by Lokon Pharma AB, H2 2019
Gallbladder Cancer - Pipeline by Merck & Co Inc, H2 2019
Gallbladder Cancer - Pipeline by Mina Therapeutics Ltd, H2 2019
Gallbladder Cancer - Pipeline by Molecular Templates Inc, H2 2019
Gallbladder Cancer - Pipeline by Novartis AG, H2 2019
Gallbladder Cancer - Pipeline by NuCana Plc, H2 2019
Gallbladder Cancer - Pipeline by OncoTherapy Science Inc, H2 2019
Gallbladder Cancer - Pipeline by Pfizer Inc, H2 2019
Gallbladder Cancer - Pipeline by Rafael Pharmaceuticals Inc, H2 2019
Gallbladder Cancer - Pipeline by Shanghai Haihe Biopharma Co Ltd, H2 2019
Gallbladder Cancer - Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2019
Gallbladder Cancer - Pipeline by Sinocelltech Ltd, H2 2019
Gallbladder Cancer - Pipeline by SMT bio Co Ltd, H2 2019
Gallbladder Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
Gallbladder Cancer - Pipeline by TOT Biopharm Co Ltd, H2 2019
Gallbladder Cancer - Pipeline by Turning Point Therapeutics Inc, H2 2019
Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H2 2019
Gallbladder Cancer - Pipeline by XuanZhu Pharma Co Ltd, H2 2019
Gallbladder Cancer - Pipeline by Zymeworks Inc, H2 2019
Gallbladder Cancer - Dormant Projects, H2 2019
Gallbladder Cancer - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Gallbladder Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4SC AG
  • Advenchen Laboratories LLC
  • Almac Discovery Ltd
  • Alphamab Oncology
  • Andes Biotechnologies
  • Apexian Pharmaceuticals Inc
  • Apollomics Inc
  • Aslan Pharmaceuticals Ltd
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd
  • Bristol-Myers Squibb Co
  • Delta-Fly Pharma Inc
  • Diverse Biotech Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Faron Pharmaceuticals Oy
  • Hutchison MediPharma Ltd
  • Infinity Pharmaceuticals Inc
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Karus Therapeutics Ltd
  • Kringle Pharma Inc
  • Leap Therapeutics Inc
  • Lokon Pharma AB
  • Merck & Co Inc
  • Mina Therapeutics Ltd
  • Molecular Templates Inc
  • Novartis AG
  • NuCana Plc
  • OncoTherapy Science Inc
  • Pfizer Inc
  • Rafael Pharmaceuticals Inc
  • Shanghai Haihe Biopharma Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Sinocelltech Ltd
  • SMT bio Co Ltd
  • Taiho Pharmaceutical Co Ltd
  • TOT Biopharm Co Ltd
  • Turning Point Therapeutics Inc
  • VasGene Therapeutics Inc
  • XuanZhu Pharma Co Ltd
  • Zymeworks Inc
Note: Product cover images may vary from those shown
Adroll
adroll